In accordance with previous studies,25, 28, 29, 31, 32 we observed more aggressive BC subtypes with high nuclear grade and positive HER2‐status or luminal‐B‐(like)‐phenotype in women with LFS, necessitating neo‐ or adjuvant‐systemic therapy. This evidence concerns the gene ERBB2 and breast cancer.